首页> 外文期刊>Cancer biology & therapy >Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responsesto rapamycin
【24h】

Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responsesto rapamycin

机译:鉴定增强对雷帕霉素的细胞毒性反应的Akt选择性细胞毒性化合物

获取原文
获取原文并翻译 | 示例
           

摘要

We performed a high-throughput screen to identify compounds with a selective ability to induce apoptosis in Akt-expressing cells without disrupting Bcl-x_L-dependent survival. Results showed that a screening strategy based on Alamar Blue underrepresented the viability of Bcl-x_L-expressing cells relative to Akt-expressing cells, possibly due to metabolic differences between the two cell survival programs. Using an alternative screen based on plasma membrane integrity, we identified several compounds that target Akt-dependent survival without toxic effect to Bcl-x_L-dependent survival. These compounds enhanced the cytotoxic potential of rapamycin, a chemotherapeutic that inhibits survival signaling downstream of Akt. The results demonstrate a screening method and the subsequent identification of two compounds with selective activity in counteracting Akt-dependent cell survival.
机译:我们进行了高通量筛选,以鉴定具有选择性诱导Akt表达细胞凋亡而不破坏Bcl-x_L依赖生存的化合物。结果表明,基于Alamar Blue的筛选策略不能充分表达Bcl-x_L表达细胞相对于Akt表达细胞的生存能力,这可能是由于两个细胞存活程序之间的代谢差异所致。使用基于质膜完整性的替代筛选,我们确定了几种靶向Akt依赖生存而对Bcl-x_L依赖生存无毒作用的化合物。这些化合物增强了雷帕霉素的细胞毒性潜力,雷帕霉素是一种化学疗法,可抑制Akt下游的生存信号。结果证明了筛选方法和随后鉴定的两种具有选择性活性的化合物可抵消Akt依赖的细胞存活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号